C12N 9/6432
Coagulation factor xa
Official title: {Coagulation factor Xa (3.4.21.6)}
C12N9/6432 (Coagulation factor xa) appears on 136 US grants and 188 published applications in this corpus.
Search patents in C12N- Granted patents
- 136
- Published applications
- 188
- Assignees
- 95
- Inventors
- 266
- Latest grant
- 26 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 5 | 0 |
| 1998 | 5 | 0 |
| 1999 | 4 | 0 |
| 2000 | 8 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 5 |
| 2003 | 6 | 19 |
| 2004 | 3 | 10 |
| 2005 | 3 | 8 |
| 2006 | 2 | 3 |
| 2007 | 2 | 0 |
| 2008 | 3 | 3 |
| 2009 | 0 | 8 |
| 2010 | 2 | 7 |
| 2011 | 1 | 5 |
| 2012 | 6 | 7 |
| 2013 | 4 | 6 |
| 2014 | 7 | 15 |
| 2015 | 7 | 11 |
| 2016 | 9 | 12 |
| 2017 | 6 | 10 |
| 2018 | 8 | 9 |
| 2019 | 4 | 7 |
| 2020 | 10 | 9 |
| 2021 | 7 | 12 |
| 2022 | 3 | 7 |
| 2023 | 3 | 2 |
| 2024 | 3 | 6 |
| 2025 | 3 | 7 |
By publication year. Applications have been published since 2001.
Recent patents
- Compositions and methods for preparing factor Xa and derivatives26 Aug 2025US 12,398,387 B2Alexion Pharmaceuticals, Inc.
- FX activation process and its use in the preparation of a FXa composition15 Apr 2025US 12,274,738 B2Octapharma AG
- Antidotes to factor XA inhibitors14 Jan 2025US 12,195,774 B2Alexion Pharmaceuticals, Inc.
- Highly potent ISVD compounds capable of substituting for FVIII(A)24 Sep 2024US 12,098,400 B2Novo Nordisk A/S
- Prohemostatic proteins for the treatment of bleeding10 Sep 2024US 12,083,170 B2Academisch Ziekenhuis Leiden
- Improved anti-albumin nanobodies and their uses25 Dec 2025US 2025/0388663 A1Institut National de la Sante et de la Recherche Medicale
- Modified factor xa polypeptides and methods of use2 Oct 2025US 2025/0302927 A1The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- Fx activation process and its use in the preparation of a fxa composition10 Jul 2025US 2025/0222079 A1Octapharma AG
- Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same12 Jun 2025US 2025/0186563 A1Alexion Pharmaceuticals, Inc.
- Lyophilized formulations for factor xa antidote22 May 2025US 2025/0163399 A1Alexion Pharmaceuticals, Inc.
Most cited
By later US patents
- Pharmaceutical preparation for treating blood coagulation disorders81US 6,224,862 B1Baxter Aktiengesellschaft · 2001
- Antithrombosis agents64US 5,278,144 ACOR Therapeutics, Inc. · 1994
- Interative method of at least three cycles for the refolding of proteins41US 5,739,281 ADenzyme APS · 1998
- Iterative method of at least five cycles for the refolding of proteins38US 5,917,018 ADenzyme APS · 1999
- Chimeric serine proteases37US 6,660,492 B1Boehringer Mannheim GmbH · 2003